Guardant Health (NASDAQ:GH) CEO Amirali Talasaz Sells 37,500 Shares

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 37,500 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $169.16, for a total value of $6,343,500.00. Following the completion of the sale, the chief executive officer owned 37,500 shares of the company’s stock, valued at approximately $6,343,500. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 26th, Amirali Talasaz sold 116,972 shares of Guardant Health stock. The shares were sold at an average price of $150.79, for a total transaction of $17,638,207.88.
• On Monday, June 29th, Amirali Talasaz sold 143,028 shares of Guardant Health stock. The shares were sold at an average price of $151.54, for a total transaction of $21,674,463.12.

Guardant Health Price Performance

Shares of Guardant Health stock traded down $7.51 during trading on Monday, hitting $163.18. The stock had a trading volume of 2,211,234 shares, compared to its average volume of 2,311,072. Guardant Health, Inc. has a 12 month low of $53.40 and a 12 month high of $176.58. The firm’s fifty day simple moving average is $153.91 and its 200-day simple moving average is $118.72. The stock has a market cap of $21.90 billion, a PE ratio of -46.76 and a beta of 1.60.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to analysts’ expectations of $314.23 million. The business’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same period last year, the company earned ($0.44) earnings per share. Analysts expect that Guardant Health, Inc. will post -2.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Guardant Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. ABS Investment Management LLC purchased a new stake in Guardant Health in the second quarter worth about $345,069,000. TrinityBridge Ltd bought a new stake in shares of Guardant Health in the 2nd quarter valued at about $45,000. Elyxium Wealth LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at about $35,000. Parallel Advisors LLC lifted its position in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the period. Finally, Global Retirement Partners LLC purchased a new stake in shares of Guardant Health in the 2nd quarter worth approximately $59,000. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Piper Sandler boosted their price objective on Guardant Health from $135.00 to $193.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. BTIG Research lifted their target price on Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Sanford C. Bernstein upped their price target on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, July 2nd. JPMorgan Chase & Co. raised their price target on shares of Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Mizuho lifted their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Guardant Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.